Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).
INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
Numinus Pilots Mental Health Program for Corporate Clients in Utah
Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum
Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.
Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics
Optimi files an application with Health Canada to synthesize, process and produce pharmaceutical grade 3,4-Methylenedioxymethamphetamine ("MDMA").
Numinus completes acquisition of Novamind and announces executive appointments
Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.